← InSilico Medicine Cayman TopCo overview

InSilico Medicine Cayman TopCo vs Innovent Biologics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

InSilico Medicine Cayman TopCo (3696.HK)

Q2 2026
▲4

Insilico's AI drug platform wins big pharma deals and turns profitable

  • Two major pharma deals validate AI platform Insilico signed a $2.5B deal with SK Biopharmaceuticals and a $600M collaboration with Takeda, bringing near-term cash and potential milestones. These deals show major drugmakers trust Insilico's AI to discover new medicines, which can drive future revenue and profit.

    These are the largest new partnerships this period and directly boost demand for Insilico's platform.

  • First-half profit forecast and Phase III trial progress Insilico expects H1 2026 net profit of $33.5–39.5 million on revenue up ~280% to ~$105 million, driven by out-licensing. Its lead AI-designed drug Rentosertib entered Phase III for lung scarring, the first AI-derived asset to reach that stage. This shows the business can make money and advance drugs.

    Profitability and late-stage clinical progress are key new proof points that can re-rate the stock.

  • Added to healthcare tech index, attracting passive funds Insilico joined the Healthcare Technology and Innovation index, which can bring in automatic buying from funds that track it. This adds steady demand for the shares and raises the company's profile among institutional investors.

    Index inclusion is a new capital-flow catalyst that can support the share price.

  • Sector rebound and platform out-licensing trend The innovative drug sector rebounded, with China's out-licensing deals nearing $100 billion in H1 2026. Insilico's Takeda deal is cited as a landmark showing Chinese firms now license entire technology platforms, not just single drugs. This tailwind lifts sentiment for the whole sector, including Insilico.

    It explains the broader industry force behind Insilico's deal momentum and investor interest.

June 2026
▲4

Insilico's AI drug platform wins big pharma deals and turns profitable

  • Two major pharma deals validate AI platform Insilico signed a $2.5B deal with SK Biopharmaceuticals and a $600M collaboration with Takeda, bringing near-term cash and potential milestones. These deals show major drugmakers trust Insilico's AI to discover new medicines, which can drive future revenue and profit.

    These are the largest new partnerships this period and directly boost demand for Insilico's platform.

  • First-half profit forecast and Phase III trial progress Insilico expects H1 2026 net profit of $33.5–39.5 million on revenue up ~280% to ~$105 million, driven by out-licensing. Its lead AI-designed drug Rentosertib entered Phase III for lung scarring, the first AI-derived asset to reach that stage. This shows the business can make money and advance drugs.

    Profitability and late-stage clinical progress are key new proof points that can re-rate the stock.

  • Added to healthcare tech index, attracting passive funds Insilico joined the Healthcare Technology and Innovation index, which can bring in automatic buying from funds that track it. This adds steady demand for the shares and raises the company's profile among institutional investors.

    Index inclusion is a new capital-flow catalyst that can support the share price.

  • Sector rebound and platform out-licensing trend The innovative drug sector rebounded, with China's out-licensing deals nearing $100 billion in H1 2026. Insilico's Takeda deal is cited as a landmark showing Chinese firms now license entire technology platforms, not just single drugs. This tailwind lifts sentiment for the whole sector, including Insilico.

    It explains the broader industry force behind Insilico's deal momentum and investor interest.

Latest
▲4

Insilico's AI drug platform wins big pharma deals and turns profitable

  • Two major pharma deals validate AI platform Insilico signed a $2.5B deal with SK Biopharmaceuticals and a $600M collaboration with Takeda, bringing near-term cash and potential milestones. These deals show major drugmakers trust Insilico's AI to discover new medicines, which can drive future revenue and profit.

    These are the largest new partnerships this period and directly boost demand for Insilico's platform.

  • First-half profit forecast and Phase III trial progress Insilico expects H1 2026 net profit of $33.5–39.5 million on revenue up ~280% to ~$105 million, driven by out-licensing. Its lead AI-designed drug Rentosertib entered Phase III for lung scarring, the first AI-derived asset to reach that stage. This shows the business can make money and advance drugs.

    Profitability and late-stage clinical progress are key new proof points that can re-rate the stock.

  • Added to healthcare tech index, attracting passive funds Insilico joined the Healthcare Technology and Innovation index, which can bring in automatic buying from funds that track it. This adds steady demand for the shares and raises the company's profile among institutional investors.

    Index inclusion is a new capital-flow catalyst that can support the share price.

  • Sector rebound and platform out-licensing trend The innovative drug sector rebounded, with China's out-licensing deals nearing $100 billion in H1 2026. Insilico's Takeda deal is cited as a landmark showing Chinese firms now license entire technology platforms, not just single drugs. This tailwind lifts sentiment for the whole sector, including Insilico.

    It explains the broader industry force behind Insilico's deal momentum and investor interest.

Innovent Biologics Inc (1801.HK)

Q3 2026
▲3▼1

Innovent advances pipeline, licensing, and revenue; risks persist

  • Pipeline and licensing progress Innovent started Phase 3 trials for a fast-tracked myeloma antibody, gained China rights to Verzenio and Vanflyta, licensed IBI355 to Spero for up to $1.1B, and filed the world's first weekly oral GLP-1.

    These pipeline and licensing moves are key new developments that can drive future growth and investor optimism.

  • Strong revenue growth First-half product revenue rose over 55% to 8.2 billion yuan, showing strong commercial execution and underlying business momentum.

    Revenue growth is a fundamental driver of stock performance and reflects the company's financial health.

  • Sector re-rating on licensing activity A sector re-rating driven by record Chinese licensing activity boosted valuations across the biotech space, lifting Innovent's shares.

    This external factor improved sentiment and valuation multiples for the entire sector, including Innovent.

  • Risks from trial and deal flow Sector rallies can cool if deal flow slows, and pipeline bets like IBI3003 and IBI3042 depend on costly, uncertain late-stage trials and regulatory outcomes.

    These risks could negatively impact the stock if they materialize, providing a balanced view.

August 2026
▲4

Innovent adds Daiichi deal and weekly GLP-1 filing as sector re-rates

  • World-first weekly oral GLP-1 enters clinic Innovent's IBI3042 became the first small-molecule weekly oral GLP-1 to reach clinical stage, with China's drug regulator accepting the filing. A once-weekly pill would be easier for patients than injections, so success could open a large obesity and diabetes market and lift long-term sales hopes.

    New pipeline milestone that expands Innovent's biggest growth opportunity beyond current products.

  • Wins China rights to Daiichi Sankyo's Vanflyta Innovent secured exclusive China commercialization rights for Vanflyta, a leukemia drug approved in June 2026, while Daiichi Sankyo handles development and supply. This adds a near-term oncology product to sell through Innovent's existing hospital network, lifting revenue without big new research spending.

    A concrete new commercial deal that adds revenue and shows Innovent's partnering strength.

  • First-half product revenue up over 55% Innovent's first-half product revenue topped 8.2 billion yuan, up more than 55% year on year, reported alongside strong results from BeiGene and RemeGen. Faster product sales show its medicines are being adopted widely, which supports profit growth and gives the stock a fundamental reason to rise.

    Actual reported sales growth is the core evidence behind the share price move.

  • Sector re-rating on record licensing and Moderna data Chinese drug licensing deals hit about $99.7 billion in the first half, roughly double all of 2024, and Moderna's cancer vaccine success lifted biotech shares globally. Innovent landed billion-dollar overseas deals, so investors are paying more for its pipeline. Counterweight: sector rallies can cool if deal flow slows.

    Explains the broad demand backdrop pushing innovative drug stocks, including Innovent, higher.

Latest
▲4

Innovent adds Daiichi deal and weekly GLP-1 filing as sector re-rates

  • World-first weekly oral GLP-1 enters clinic Innovent's IBI3042 became the first small-molecule weekly oral GLP-1 to reach clinical stage, with China's drug regulator accepting the filing. A once-weekly pill would be easier for patients than injections, so success could open a large obesity and diabetes market and lift long-term sales hopes.

    New pipeline milestone that expands Innovent's biggest growth opportunity beyond current products.

  • Wins China rights to Daiichi Sankyo's Vanflyta Innovent secured exclusive China commercialization rights for Vanflyta, a leukemia drug approved in June 2026, while Daiichi Sankyo handles development and supply. This adds a near-term oncology product to sell through Innovent's existing hospital network, lifting revenue without big new research spending.

    A concrete new commercial deal that adds revenue and shows Innovent's partnering strength.

  • First-half product revenue up over 55% Innovent's first-half product revenue topped 8.2 billion yuan, up more than 55% year on year, reported alongside strong results from BeiGene and RemeGen. Faster product sales show its medicines are being adopted widely, which supports profit growth and gives the stock a fundamental reason to rise.

    Actual reported sales growth is the core evidence behind the share price move.

  • Sector re-rating on record licensing and Moderna data Chinese drug licensing deals hit about $99.7 billion in the first half, roughly double all of 2024, and Moderna's cancer vaccine success lifted biotech shares globally. Innovent landed billion-dollar overseas deals, so investors are paying more for its pipeline. Counterweight: sector rallies can cool if deal flow slows.

    Explains the broad demand backdrop pushing innovative drug stocks, including Innovent, higher.

July 2026
▲4

Innovent advances novel drugs and expands commercial reach

  • Tri-specific antibody enters Phase 3 Innovent dosed the first patient in a Phase 3 trial of IBI3003 for multiple myeloma. This novel therapy showed strong early results and has FDA Fast Track status. Success could add a major new treatment to Innovent's pipeline, boosting future revenue prospects.

    This is a new clinical milestone that could lead to a new drug approval and revenue stream.

  • Ollin raises $330M for eye drug Innovent's partner Ollin Biosciences raised $330 million to fund global Phase 3 trials of an eye drug discovered by Innovent. The trials will include China and South Korea. This validates Innovent's research and could bring milestone payments and royalties.

    This is new partnership progress that could generate future revenue for Innovent.

  • Gains China rights to Verzenio Eli Lilly handed over sole commercialization rights for breast cancer drug Verzenio in mainland China to Innovent. The drug had about $221 million in sales last year. This expands Innovent's oncology portfolio and adds immediate revenue.

    This is a new commercial agreement that directly boosts Innovent's product sales.

  • Licenses anti-CD40L antibody to Spero Innovent licensed IBI355, an autoimmune disease antibody, to Spero Therapeutics outside Greater China in a deal worth up to $1.1 billion. Innovent gets an upfront payment and potential milestones and royalties, while keeping China rights.

    This is a new out-licensing deal that provides cash and validates Innovent's pipeline.

▲4

Innovent advances novel drugs and expands commercial reach

  • Tri-specific antibody enters Phase 3 Innovent dosed the first patient in a Phase 3 trial of IBI3003 for multiple myeloma. This novel therapy showed strong early results and has FDA Fast Track status. Success could add a major new treatment to Innovent's pipeline, boosting future revenue prospects.

    This is a new clinical milestone that could lead to a new drug approval and revenue stream.

  • Ollin raises $330M for eye drug Innovent's partner Ollin Biosciences raised $330 million to fund global Phase 3 trials of an eye drug discovered by Innovent. The trials will include China and South Korea. This validates Innovent's research and could bring milestone payments and royalties.

    This is new partnership progress that could generate future revenue for Innovent.

  • Gains China rights to Verzenio Eli Lilly handed over sole commercialization rights for breast cancer drug Verzenio in mainland China to Innovent. The drug had about $221 million in sales last year. This expands Innovent's oncology portfolio and adds immediate revenue.

    This is a new commercial agreement that directly boosts Innovent's product sales.

  • Licenses anti-CD40L antibody to Spero Innovent licensed IBI355, an autoimmune disease antibody, to Spero Therapeutics outside Greater China in a deal worth up to $1.1 billion. Innovent gets an upfront payment and potential milestones and royalties, while keeping China rights.

    This is a new out-licensing deal that provides cash and validates Innovent's pipeline.

© 2026 MarketIVWhy